Live Good Inc. sold Berry Gen Sugar Control supplements as a diabetes treatment without FDA approval, making it an unapproved, misbranded drug.
What happened
FDA reviewed the company's website (berrygen.com), its linked Facebook and Instagram pages, and its Amazon storefront in August 2021, and the Federal Trade Commission reviewed the websites at the same time. FDA found claims that Berry Gen Sugar Control reduces blood sugar, controls glucose, regulates insulin, protects the pancreas and helps control diabetes. FDA says these claims make the supplement a drug, and one sold without approval and without adequate directions for use.
What FDA found
The website, social media and Amazon claims that the product treats or prevents diabetes and controls blood sugar show it is intended as a drug.
Federal Food, Drug, and Cosmetic Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]The product is not generally recognized as safe and effective for these uses, so it is a new drug sold without FDA approval.
Sections 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]The product does not carry adequate directions for use, because treating diabetes safely needs a licensed practitioner.
Section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 C.F.R. 201.5Shipping this misbranded drug across state lines violates the Act.
Section 301(a) [21 U.S.C. 331(a)]The FTC says the diabetes treatment claims are not backed by competent and reliable scientific evidence, such as well-controlled human clinical studies.
FTC Act, 15 U.S.C. ยง 45
What FDA wants
Write to FDA within 15 working days describing each step taken to fix the violations and prevent them from recurring, with supporting documents, or explain why more time is needed. The FTC separately asks for notice within 15 working days of actions taken on the advertising claims.
Who should pay attention
- dietary supplement brands making blood sugar or diabetes claims
- Amazon sellers and marketplace listing teams
- marketers running social media ads, including in Spanish
This is a summary. Read the original letter on fda.gov.